0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Respiratory Drugs Market Research Reports

Asthma - Competitive landscape, 2023 - Product Thumbnail Image

Asthma - Competitive landscape, 2023

  • Report
  • April 2023
  • 240 Pages
  • Global
From
EUR$3,500USDGBP
From
EUR$7,500USDGBP
Respiratory Syncytial Virus (RSV) - Epidemiology Forecast - 2032 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV) - Epidemiology Forecast - 2032

  • Report
  • February 2023
  • 82 Pages
  • Global
From
EUR$3,950USDGBP
From
EUR$7,500USDGBP
Treprostinil Palmitil Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Treprostinil Palmitil Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
EUR$3,250USDGBP
LIQ-861 Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

LIQ-861 Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
EUR$2,750USDGBP
Tralokinumab Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Tralokinumab Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
EUR$2,750USDGBP
Lebrikizumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Lebrikizumab Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
EUR$3,250USDGBP
Treprostinil sodium Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Treprostinil sodium Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
EUR$2,750USDGBP
FASENRA (Benralizumab) Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

FASENRA (Benralizumab) Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • September 2022
  • 30 Pages
  • Global
From
EUR$3,250USDGBP
XOLAIR Marketed Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

XOLAIR Marketed Drug Insight and Market Forecast - 2032

  • Report
  • September 2022
  • 30 Pages
  • Global
From
EUR$2,750USDGBP
Benralizumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Benralizumab Emerging Drug Insight and Market Forecast - 2032

  • Report
  • September 2022
  • 30 Pages
  • Global
From
EUR$3,250USDGBP
From
EUR$3,950USDGBP
From
EUR$7,500USDGBP
Chronic Refractory Cough (CRC) - Epidemiology Forecast - 2032 - Product Thumbnail Image

Chronic Refractory Cough (CRC) - Epidemiology Forecast - 2032

  • Report
  • August 2022
  • 77 Pages
  • Global
From
EUR$3,950USDGBP
From
EUR$7,500USDGBP
Idiopathic Pulmonary Fibrosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast - 2032

  • Report
  • August 2022
  • 109 Pages
  • Global
From
EUR$3,950USDGBP
From
EUR$3,250USDGBP
XOLAIR Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

XOLAIR Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
EUR$3,250USDGBP
From
EUR$7,500USDGBP
Loading Indicator

The Respiratory Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat respiratory diseases. These drugs are used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Commonly prescribed respiratory drugs include bronchodilators, corticosteroids, and antibiotics. The Respiratory Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Novartis, and Boehringer Ingelheim. These companies are constantly researching and developing new drugs to treat respiratory diseases, as well as improving existing treatments. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more